Introduction: Published data regarding intradetrusor injection of onabotulinumtoxinA in adults with congenital spinal dysraphism are scarce. We retrospectively investigated the outcomes of intradetrusor injection of onabotulinumtoxinA in this setting.
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Abbreviations and Acronyms
Spinal dysraphism such as spina bifida may lead to paralysis of the legs, and urine and stool incontinence. 1 Although major reconstructive urological surgeries still have an important role in caring for these patients, 2 during the last few decades much progress has been made to improve urinary incontinence in these patients using conservative modalities such as clean intermittent catheterization and medications. 3 Some patients do not respond to oral medications or their neurogenic constipation can be worsened by the anticholinergic side effects. Intradetrusor injection of onabotulinumtoxinA has been used by various groups to delay or avoid the need for augmentation cystoplasty. 4 Nevertheless, almost all published studies regarding intradetrusor injection of OnabotA in patients with spinal dysraphism have been done in pediatric or adolescent age groups. 5 Studies are lacking regarding onabotulinumtoxinA efficacy in adults with congenital spinal dysraphism who might present with more advanced disease with a fibrotic bladder and decreased bladder compliance. The strongest data supporting the use of onabotulinumtoxinA for neurogenic detrusor overactivity in adults comes from the DIG-NITY clinical research program, which only recruited patients with multiple sclerosis and spinal cord injuries. 6, 7 Despite some similarities to patients with multiple sclerosis and spinal cord injury, adult patients with congenital spinal dysraphism represent a distinct group of patients with neurogenic bladder. We hypothesized that although onabotulinumtoxinA has some clinical efficacy in adults with congenital spinal dysraphism, a substantial number of patients would not benefit from this intervention due to their advanced bladder disease.
Methods
Billing codes were used to identify 149 patients who underwent OnabotA injection in the clinic or the operating room between 2012 and 2016 at our tertiary transitional urology clinic. Charts were reviewed to determine which patients had any form of congenital spinal dysraphism. Detailed retrospective chart review was performed before and after intradetrusor OnabotA injections to explore the outcome of this treatment for UI. Our current institution policy is to start with intradetrusor injection of OnabotA 200 U and increase to 300 U if it fails (low response or early deterioration of response) in the neurogenic detrusor overactivity setting when anticholinergics have failed or patients are unable to tolerate the medications. In this retrospective study 5 injections of BotoxÒ 300 U were done in 2 patients in 2014 based on physician discretion. All other patients received 200 U throughout the study period. All patients had UI through their native urethra or stoma at baseline. UI improved with OnabotA injection in 81.2% of patients and of these 63.6% became completely dry (p¼0.023). After excluding 1 patient with end stage renal disease who needed renal transplantation at baseline, mean GFR before and 13.3 (AE9) months after treatment was 100.2 (AE17.2) and 120.1 (AE16.6) ml/minute/1.73 m 2 , respectively (p¼0.41). Hydronephrosis improved in 3 of 4 (75%) patients who had followup ultrasound while it did not change in the other patient (25%). Pretreatment bladder compliance in the patient in whom the degree of hydronephrosis did not improve was 10.8 ml/cm H 2 O. This finding is in contrast to the patients in whom hydronephrosis improved where mean bladder compliance was 44.3 (AE14) ml/cm H 2 O.
Repeat urodynamic study after OnabotA injection was done in 11 (61.1%) patients who had persistent or unchanged UI or were categorized as high risk as previously defined. Maximum cystometric capacity improved following OnabotA injection from 310.18 (74.12) to 380.27 (107.37) ml (p¼0.045). Neurogenic detrusor overactivity was observed in 62.5% and 50% of patients before and after treatment, respectively (p¼0.5). Mean bladder compliance in 6 (33.3%) patients with decreased baseline compliance before and after treatment was 8.97 (AE2.71) and 18.1 (AE12.7) ml/cm H 2 O, respectively (p¼0.11).
In terms of vesicoureteral reflux our cohort had 7 patients with low grade vesicoureteral reflux at baseline (grade 1-2). Mean compliance in this group was 23.58 ml/cm H 2 O (range 6.8 to 64.3). Mean compliance after treatment in the VUR group was 26.15 ml/cm H 2 O (range 10.3 to 52.8). Presence of "pop-off" mechanisms such as high grade VUR into dilated upper urinary tracts may hinder appropriate bladder compliance measurement. 8, 9 However, in our cohort vesicoureteral reflux was mainly grade 1 and 2, and it is possible that its effect on pressure measurements during filling was minimal.
Discussion
Spinal dysraphism encompasses a spectrum from tethered cord to spina bifida to sacral agenesis, with spina bifida being the most common type. Spina bifida is estimated to occur in 3.1 per 10,000 children and adolescents 0 to 19 years old and 3.3 per 10,000 adolescents 16 to 19 years old in the United States. 10 The goals of urological management in patients with neurogenic bladder and spinal dysraphism include protection of renal function, bladder and bowel continence, and improving quality of life. 3 With transition to adulthood more attention is directed to urinary and bowel continence. 11 Reconstructive surgeries have been the most successful option in the management of UI in this setting. However, they are invasive and costly, and complications are common. 3 Conservative modalities are considered first, including clean intermittent catheterization and oral medications. Some patients do not respond to oral medications or their neurogenic constipation is worsened by medication side effects, and intradetrusor injection of various forms of botulinum toxin A (onabotulinumtoxinA and abobotulinumtoxinA) has been used in children with refractory UI. 4 In a small subset of patients the goals are not achieved or do not last in the long term following reconstructive procedures such as augmentation cystoplasty, and there is little guidance on how to proceed next. Traditionally if conservative measures such as anticholinergics and clean intermittent catheterization fail, repeat augmentation is performed. 12 However, OnabotA injection may represent a less invasive option and it was applied to a subset of patients in this cohort. A systematic review was performed by Hascoet et al in 2016 that included 12 studies and 293 patients all younger than 18 years old. 13 Complete resolution of incontinence occurred in 32% to 100% of patients. 13e24 MCC increased from 27% to 162% in different studies. 13e17,19e22,24,25 Two studies implied that botulinum toxin A has lower efficacy in patients with low bladder compliance. 13, 16, 23 To our knowledge, there have been no reports on the intradetrusor use of OnabotA injection in adult patients with congenital spinal dysraphism, representing a distinct group of patients with neurogenic bladder dysfunction. 13 Our study, which specifically focuses on adults with spinal dysraphism with a mean age of 20.76 (AE3.03) years at the time of the initial OnabotA injection, showed that UI improved by OnabotA injection in 81.25% of patients and 63.66% of them became dry. Mean MCC, which might have a role in dryness, also improved significantly with the treatment. The other goal was preservation of renal function in this setting. Our short-term followup data show that mean GFR was stable and hydronephrosis improved in most patients who had hydronephrosis before treatment. However, hydronephrosis did not improve in 1 patient with baseline decreased compliance of 10.8 ml/cm H 2 O.
Our study shows that compliance may not improve with OnabotA injection in adult patients with decreased compliance at baseline, which is consistent with prior studies in children. In a study by Horst et al bladder compliance did not improve with OnabotA injection in 10 of 11 children with neurogenic bladder who had poor baseline compliance. 16 Tiryaki et al also concluded that botulinum injection is useless in fibrotic neuropathic bladders with poor baseline compliance. 23 Limitations of our study include the retrospective nature with small numbers of patients and a relatively short followup. Additionally, we only had available estimated GFR (calculated based on serum creatinine), which is a poor marker to assess renal function in this patient population, who often have decreased overall muscle mass. 26 Accruing a large number of adult patients with congenital spinal dysraphism is difficult in most centers, even in tertiary centers with a large number of referrals of patients with neurogenic bladder, thus highlighting the need for multicenter investigations in the future. It appears that in patients with spinal dysraphism, earlier intervention with OnabotA at a younger age, before significant bladder remodeling and loss of compliance, may be more beneficial. Single center data such as the current cohort may limit our understanding of this important issue. Future prospective and multicenter trials are needed to better evaluate the effects of OnabotA in adults with spinal dysraphism and UI.
In conclusion, intradetrusor OnabotA injection may improve refractory UI in adults with spinal dysraphism. However, despite improvement in MCC, bladder compliance may not improve following therapy in patients who had loss of compliance at baseline. Earlier intervention might be more beneficial in this specific patient population.
